Combination of photocoagulation and intravitreal injection of
pegaptanib or  bevacizumab in treatment of stage 3 retinopathy
of prematurity in zone I or posterior zone II

k 2011

Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II

ŠENKOVÁ, Kateřina; Rudolf AUTRATA; Edita UNČOVSKÁ; Marie HOLOUŠOVÁ; Inka KREJČÍŘOVÁ et al.

Základní údaje

Originální název

Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II

Autoři

ŠENKOVÁ, Kateřina; Rudolf AUTRATA; Edita UNČOVSKÁ; Marie HOLOUŠOVÁ a Inka KREJČÍŘOVÁ

Vydání

37th meeting of European Paediatric Ophthalmological Society : Visual Impairment in Childhood, 2011

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00054211

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

photocoagulation; pegaptanib; bevacizumab; retinopathy of prematurity

Změněno: 5. 1. 2012 08:55, prof. MUDr. Rudolf Autrata, CSc., MBA

Anotace

V originále

Purpose: To report results of retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of pegaptanib or bevacizumab and diode laser photocoagulation. 32 infants weighing from 545 g to 1,150 g at birth (mean, 742.8 g) with gestational ages from 22 weeks to 28 weeks (mean, 24.1 weeks) received intravitreal injections of pegaptanib (0,15mg) or bevacizumab (0.625 mg ) at 9.0 weeks to 14.0 weeks of age (mean, 10.5 weeks) and after 1 week had diode laser therapy. Length of follow-up was from 15.0 weeks to 95.0 weeks (mean, 56.5 weeks). Only patients with bilateral moderate or severe stage 3 ROP in Zone I or posterior Zone II with or without plus-disease were considered candidates for this study. All cases were photographed by the RetCam Imaging System immediately before and 1week, 1,2, and 3months after the bilateral treatment. Each infant underwent photography at the time of the most recent examination to demonstrate the extent of continued vascular growth anteriorly from the original location of moderate or severe stage. All 64 eyes were treated successfully (no retinal detachment, macular ectopia, high myopia, anisometropia, or other ocular abnormalities) to induce regression of acute ROP with only 1 injection and 1 laser treatment. These results are promising, without any early local or systemic complications. Intravitreal injection of pegaptanib or bevacizumab combinated with photocoagulation was safe and effective in treating stage 3 ROP in zone I and posterior zone II in this series of 32 infants. A prospective, randomized, controlled, clinical trials with more patients would be initiated to investigate and confirm results of this promising treatment combination.

Citovat

ŠENKOVÁ, Kateřina; Rudolf AUTRATA; Edita UNČOVSKÁ; Marie HOLOUŠOVÁ a Inka KREJČÍŘOVÁ. Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. In 37th meeting of European Paediatric Ophthalmological Society : Visual Impairment in Childhood. 2011.

@proceedings{960894,
   author = {Šenková, Kateřina and Autrata, Rudolf and Unčovská, Edita and Holoušová, Marie and Krejčířová, Inka},
   booktitle = {37th meeting of European Paediatric Ophthalmological Society : Visual Impairment in Childhood},
   keywords = {photocoagulation; pegaptanib; bevacizumab; retinopathy of prematurity},
   language = {eng},
   note = {poster},
   title = {Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II},
   year = {2011}
}

TY  - CONF
ID  - 960894
AU  - Šenková, Kateřina - Autrata, Rudolf - Unčovská, Edita - Holoušová, Marie - Krejčířová, Inka
PY  - 2011
TI  - Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II
N1  - poster
KW  - photocoagulation
KW  - pegaptanib
KW  - bevacizumab
KW  - retinopathy of prematurity
N2  - Purpose: To report results of retrospective, consecutive, noncomparative case series of moderate and severe stage 3 retinopathy of prematurity (ROP) in zone I or posterior zone II treated by bilateral intravitreal injections of pegaptanib or bevacizumab and diode laser photocoagulation. 32 infants weighing from 545 g to 1,150 g at birth (mean, 742.8 g) with gestational ages from 22 weeks to 28 weeks (mean, 24.1 weeks) received intravitreal injections of pegaptanib (0,15mg) or bevacizumab (0.625 mg ) at 9.0 weeks to 14.0 weeks of age (mean, 10.5 weeks) and after 1 week had diode laser therapy. Length of follow-up was from 15.0 weeks to 95.0 weeks (mean, 56.5 weeks). Only patients with bilateral moderate or severe stage 3 ROP in Zone I or posterior Zone II with or without plus-disease were considered candidates for this study. All cases were photographed by the RetCam Imaging System immediately before and 1week, 1,2, and 3months after the bilateral treatment. Each infant underwent photography at the time of the most recent examination to demonstrate the extent of continued vascular growth anteriorly from the original location of moderate or severe stage. All 64 eyes were treated successfully (no retinal detachment, macular ectopia, high myopia, anisometropia, or other ocular abnormalities) to induce regression of acute ROP with only 1 injection and 1 laser treatment. These results are promising, without any early local or systemic complications. Intravitreal injection of pegaptanib or bevacizumab combinated with photocoagulation was safe and effective in treating stage 3 ROP in zone I and posterior zone II in this series of 32 infants. A prospective, randomized, controlled, clinical trials with more patients would be initiated to investigate and confirm results of this promising treatment combination.
ER  -

ŠENKOVÁ, Kateřina; Rudolf AUTRATA; Edita UNČOVSKÁ; Marie HOLOUŠOVÁ a Inka KREJČÍŘOVÁ. Combination of photocoagulation and intravitreal injection of pegaptanib or bevacizumab in treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. In \textit{37th meeting of European Paediatric Ophthalmological Society : Visual Impairment in Childhood}. 2011.

Přehled o publikaci